TIRZ / GLP-1

$100 – $280

people are viewing this right now

TIRZ / GLP-1 (Tirzepatide) is a dual GIP/GLP-1 peptide recognized for its powerful effects on weight loss, blood sugar regulation and metabolic health improvement. Available in 5mg and 10mg for protocols adapted to every need. For research use only.

Guarantee Safe Checkout

Research Use Only: This product is intended exclusively for research applications.
Delivers in: 24-48 hours

SKU: N/A Category: Weight Loss

Peptides Informations

Tirzepatide (TIRZ / GLP-1) is an advanced solution for weight loss and diabetes management, approved by Health Canada in 2024. This innovation is based on a revolutionary dual hormonal action that simultaneously regulates appetite, metabolism, and blood sugar levels.

HOW DOES IT WORK?

Tirzepatide simultaneously stimulates two key receptors: GLP-1R to reduce appetite, slow gastric emptying, and improve glucose management; and GIPR to support blood sugar regulation, improved satiety, and increased fat burning.

Together, these two mechanisms offer superior metabolic control and optimal weight loss results — surpassing existing GLP-1 treatments such as Ozempic or Wegovy.

KEY BENEFITS

Blood sugar regulation — stabilizes blood sugar levels, essential for people with type 2 diabetes.

Significant weight loss — average 15–20% of initial body weight, surpassing all other available treatments. Results comparable to bariatric surgery.

Cardiovascular health — reduces blood pressure, LDL cholesterol, and contributes to the prevention of cardiovascular disease.

Appetite suppression — reduces cravings and sugar urges, enabling a sustainable caloric deficit without excessive effort.

Quality of life — more energy, improved mobility, and an enhanced sense of well-being.

WHO IS IT FOR?

People with a BMI > 27 with health complications (diabetes, hypertension).

People with a BMI > 30, even without diabetes, to manage obesity and its impacts.

Those seeking an alternative to bariatric surgery or wishing to improve their quality of life through sustainable weight management.

WHAT THE STUDIES SAY

Research published in The Lancet and The New England Journal of Medicine shows that Tirzepatide is more effective than existing medications and produces results comparable to bariatric surgery, with losses of up to 20% of initial body weight.

PRODUCT DATA

Class	Dual GLP-1R + GIPR agonist
Other names	Tirzepatide, LY3298176, Mounjaro®, Zepbound®
Approval	Health Canada 2024
Form	Lyophilized powder
Purity	>99% HPLC